Australia · Delayed Price · Currency is AUD Ceretas Company Description
Ceretas Limited engages in developing a portable and non-invasive therapeutic ultrasound platform for the treatment of Alzheimer's disease and other neurodegenerative conditions in Australia.
The company offers a device that uses focused ultrasound beams directed through the skull to interact non-invasively with brain tissue.
The company’s technology operates through two primary mechanisms, including neuromodulation, which uses low-intensity focused ultrasound to stimulate neural circuits; and BBBO, which temporarily and reversibly opens the blood-brain barrier using ultrasound combined with circulating microbubbles that facilitates brain's natural clearance of amyloid-beta and tau and helps delivery of co-administered drugs to targeted brain regions.
The company was incorporated in 2024 and is based in Brisbane, Australia.
| Country | Australia |
| Founded | 2024 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| CEO | Rachel de las Heras |
Contact Details
Address: 260 Queen Street Brisbane, QLD 4000 Australia | |
| Phone | 61 7 3543 4424 |
| Website | ceretas.com.au |
Stock Details
| Ticker Symbol | CTS |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000475766 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Sam Wetzler | Co-Founder and Non-Executive Director |
| Vesa Peltonen | Chief Technology Officer |
| Dr. Anthony James Keating | Executive Director |
| Nicki Farley B.A., L.L.B. | Company Secretary |